GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BTG PLC (OTCPK:BTGGF) » Definitions » Shiller PE Ratio

BTG (BTGGF) Shiller PE Ratio : 429.17 (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is BTG Shiller PE Ratio?

As of today (2024-04-28), BTG's current share price is $51.50. BTG's E10 for the fiscal year that ended in Mar19 was $0.12. BTG's Shiller PE Ratio for today is 429.17.

The historical rank and industry rank for BTG's Shiller PE Ratio or its related term are showing as below:

BTGGF's Shiller PE Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 34.31
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BTG's adjusted earnings per share data of for the fiscal year that ended in Mar19 was $0.285. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.12 for the trailing ten years ended in Mar19.

Shiller PE for Stocks: The True Measure of Stock Valuation


BTG Shiller PE Ratio Historical Data

The historical data trend for BTG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BTG Shiller PE Ratio Chart

BTG Annual Data
Trend Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 178.25 111.45 80.99 116.02 87.22

BTG Semi-Annual Data
Sep09 Mar10 Sep10 Mar11 Sep11 Mar12 Sep12 Mar13 Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.99 - 116.02 - 87.22

Competitive Comparison of BTG's Shiller PE Ratio

For the Biotechnology subindustry, BTG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BTG's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BTG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BTG's Shiller PE Ratio falls into.



BTG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BTG's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=51.50/0.12
=429.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BTG's E10 for the fiscal year that ended in Mar19 is calculated as:

For example, BTG's adjusted earnings per share data for the fiscal year that ended in Mar19 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar19 (Change)*Current CPI (Mar19)
=0.285/107.0000*107.0000
=0.285

Current CPI (Mar19) = 107.0000.

BTG Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201003 0.066 89.400 0.079
201103 0.055 92.600 0.064
201203 0.070 95.400 0.079
201303 0.076 97.800 0.083
201403 0.112 99.300 0.121
201503 0.133 99.600 0.143
201603 0.224 100.400 0.239
201703 0.107 102.700 0.111
201803 0.041 105.100 0.042
201903 0.285 107.000 0.285

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BTG  (OTCPK:BTGGF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BTG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BTG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BTG (BTGGF) Business Description

Traded in Other Exchanges
N/A
Address
5 Fleet Place, London, GBR, EC4M 7RD
BTG is a biotechnology company that develops products in specialty areas of medicine. The company's three operating segments are interventional medicine, specialty pharmaceuticals, and licensing. Its interventional medicine focuses on oncology, vascular treatments, and pulmonology. BTG's revenue is roughly split between these three segments, while its oncology operations lead the interventional segment. The company has been known to utilize acquisitions for investing in leading therapies and capabilities.